FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum
LUPIN Share Price Target
Lupin Ltd.
Sector: Pharmaceuticals and health care
Sector: Pharmaceuticals and health care
LUPIN Long Term Analysts Rating
- ★★
- ★★
- ★★
- ★★
- ★★
3.2/5 (18 Ratings)
LUPIN Share Price *
739.9 -1.25 (-0.17%)
* (quote may be delayed)
18 LUPIN share price target reports by brokerages below. See what is analyst's view on LUPIN share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
You can also find LUPIN share price target tomorrow or next week from LUPIN discussion forum.
LUPIN Share Price Forecast - Consensus
| No. of reports in last year | 18 |
| No. of analysts | 10 |
| Average Consensus Forecast | 834.78 |
| Consensus Potential | 10.38% |
LUPIN Share Price Target - Broker Reports - 2019
Nirmal Bang
26-Nov-19
Price @ Call: 799.36
Target: 824
ACCUMULATE
Lupin, which was founded in 1968 by Shri Desh Bandhu Gupta, is currently the fifth largest company in Indian Pharmaceutical Market and fourth largest by prescription volume in the US. We initiate coverage on Lupin with an Accumulate rating and a target price of Rs824 based on 20x FY22E earnings. FY20 base earnings (ex Ranexa) stand at around Rs 21 per share.
Prabhudas Lilladher
13-Nov-19
Price @ Call: 737.25
Target: 760
HOLD
The sell-off of Kyowa at 1.8x EV/EBITDA is at justifiably lower valuation (vs. peer deals) due to inertia in Japan generic business. While the sell-off to increase concentration risk with higher contribution from US and India, there could be better option to deploy new capital (sourced from the divestment) in focused market. The efficient use of the capital may likely to increase profitability, return ratios and decrease leverage (to 0.08 fro, 0.32). With an opportunity of efficient capital allocation, there could be likely improvementin quality of earnings. We upgrade our recommendation to ‘Hold’ from ‘Reduce’ and increase TP to 760 (from Rs730) with 19.5x of FY21E.
Motilal Oswal
12-Nov-19
Price @ Call: 731.45
Target: 860
BUY
We cut our EPS estimate for FY21 by only 2% to INR37.8 as the decrease in EBITDA due to the sale of the Kyowa business is likely to be largely offset by lower depreciation/interest cost. We continue valuing LPC at 21x 12m forward earnings to arrive at a price target of INR860. We remain positive on LPC, given its healthy ANDA pipeline for the US market, limited price erosion in the US base business and the steady outperformance in the domestic formulation market. Maintain Buy.
Prabhudas Lilladher
6-Nov-19
Price @ Call: 764.92
Target: 730
REDUCE
While LPC guided for ramp up in Levothyroxyn supply and launches of injectables and gProAir (Albuterol) in US along with Fostair and Etanercept in EU in H2FY20E and FY21E, we expect lack of control on overheads will percolate lesser benefits in earnings. R&D guided to be around 10% and has possibility of flare up than guided range due to trials of key generics. The status of four plants in OAI continues to be a strong overhang in valuation due to adverse risk-return matrix. We maintain ‘Reduce’ recommendation and retain TP at Rs730.
Prabhudas Lilladher
9-Aug-19
Price @ Call: 761.2
Target: 730
REDUCE
Q1 in line; Key markets lack positive surprises
We believe that high concentration of revenues from key drugs such as gRanexa and Levothyroxin may be short-lived, given that FDA’s newstrategy of faster approvals led to reduce the longevity of complex genericsto few months. LPC’s dependence on fewer generics for its growth in USwould like to continue and render its risk-return matrix unfavorable. While R&D is guided to be limited at 10% of sales, there are possibilities of higher R&D costs due to larger clinical trials of inhalers, complex injectables and specialty products in US. We maintain ‘REDUCE’ rating and TP at Rs730.
We believe that high concentration of revenues from key drugs such as gRanexa and Levothyroxin may be short-lived, given that FDA’s newstrategy of faster approvals led to reduce the longevity of complex genericsto few months. LPC’s dependence on fewer generics for its growth in USwould like to continue and render its risk-return matrix unfavorable. While R&D is guided to be limited at 10% of sales, there are possibilities of higher R&D costs due to larger clinical trials of inhalers, complex injectables and specialty products in US. We maintain ‘REDUCE’ rating and TP at Rs730.
Karvy Stock Broking
8-Aug-19
Price @ Call: 765.18
Target: 861
HOLD
We downgrade our revenue estimates for FY20E/FY21E by 3.7%/1.5% respectively on account of downgrade in US, Europe and other markets. We upgrade our EBITDA margin by 20 bps /80 bps to 18.9%/20% for FY20E /FY21E due to lower staff expenses, other expenses and R & D. We downgrade our EPS estimates by 8.2% for FY20E to Rs 28.3 and broadly maintain our EPS estimates for FY21E at Rs 41.1. We maintain our HOLD rating on the stock with a price target of Rs 861 based on 21x FY21E.
Edelweiss
19-Jul-19
Price @ Call: 756
Target: 900
BUY
Outlook and valuation: Limited downside; maintain ‘BUY’ The stock’s current valuation of 17.5x FY21E EPS – amid depressed earnings – offers an attractive entry in our view. Encouraging respiratory and biosimilar franchise may unlock value in the long run. We maintain ‘BUY/SP’ with a TP of INR900.
HDFC Securities
17-May-19
Price @ Call: 781.35
Target: 930
BUY
We maintain a BUY on LPC following in line operational performance in 4QFY19. Our TP is revised at Rs 930/sh (22x FY21E EPS) following a 10% cut in our FY21E EPS to account for higher tax and slower ramp up in Solosec.Despite being marred by repeated US FDA issues, LPC’s visible levers for both revenue and profitability help maintain our positive stance. India franchise, valued at ~Rs 650/sh, continues to protect the downside risk.
Prabhudas Lilladher
16-May-19
Price @ Call: 783.1
Target: 730
REDUCE
We cut our FY20/21E estimates by 14-15% as we trim our EBIDTA margins to 15% vs 17% earlier due to weak consumption demand outlook in the near term. IGPL with 53,000MT capacities coming on stream by end of CY19 is set to be the third largest PAN player globally. Maintain BUY with a PT of Rs477 (Rs530 earlier) as we value IGPL at 6x EV/E or 10x PER FY21E. Maintain Buy
ICICIdirect.com
16-May-19
Price @ Call: 783.1
Target: 810
HOLD
According to the management’s assertion, the macro situation in the USgenerics space is on the mend with overall price erosion stabilising at low single digit. For FY20, it has guided for 20+ launches including key launches. However, the resolution of warning letter and clearance of Official Action Indicated (OAIs) status on plants could be a near term overhang along with progress on the margins front. Growth in India remains consistent but remains lumpy for APAC (mainly Japan). Like other pharma majors, Lupin has also chalked out a product and cost rationalisation drive. The result of this drive could be visible two to three years down the line. We arrive at our target price of | 810 based on 20x FY21E EPS of Rs 40.4.
Karvy Stock Broking
16-May-19
Price @ Call: 783.1
Target: 861
HOLD
We downgrade our revenue estimates by 2.8 %/1.1% for FY20E/FY21E on account of downgrade in India, US and API. We downgrade our EBITDA margin by 120 bps /70 bps for FY20E /FY21E due to higher staff cost, overheads and R & D. We downgrade our EPS by 20.9%/4.5% to Rs 30.8/ Rs 41 for FY20E/FY21E respectively. We downgrade our price target to Rs 861 based on 21x FY20E and maintain our HOLD rating on the stock.
Reliance Securities
16-May-19
Price @ Call: 762.25
Target: 715
REDUCE
Cutting down our earnings estimates by 35.9%/28.6% for FY20E and FY21E to factor in lower than expected 4QFY19, USFDA regulatory concerns and higher tax rates. We downgrade our recommendation to Reduce from earlier HOLD recommendation with a revised Target Price of Rs715 (from Rs803 earlier).
Elara Capital
25-Apr-19
Price @ Call: 865.92
Target: 800
SELL
Kotak Securities
24-Apr-19
Price @ Call: 856.01
Target: 840
REDUCE
HDFC Securities
11-Feb-19
Price @ Call: 818.38
Target: 985
BUY
Reliance Securities
8-Feb-19
Price @ Call: 821.75
Target: 850
HOLD
ICICIdirect.com
8-Feb-19
Price @ Call: 821.75
Target: 840
HOLD
Motilal Oswal
7-Feb-19
Price @ Call: 841.95
Target: 1000
BUY
LUPIN Share Price Target - Broker Reports - 2018
Prabhudas Lilladher
31-Oct-18
Price @ Call: 889.02
Target: 713
REDUCE
Prabhudas Lilladher
10-Aug-18
Price @ Call: 827.95
Target: 727
REDUCE
Motilal Oswal
10-Aug-18
Price @ Call: 820.75
Target: 950
BUY
Edelweiss
26-Jul-18
Price @ Call: 800
Target: 920
BUY
Investec Securities
17-May-18
Price @ Call: 766.75
Target: 665
SELL
Centrum
17-May-18
Price @ Call: 761.01
Target: 930
BUY
Edelweiss
16-May-18
Price @ Call: 750.85
Target: 780
HOLD
Prabhudas Lilladher
16-May-18
Price @ Call: 750.85
Target: 727
REDUCE
Motilal Oswal
16-May-18
Price @ Call: 750.85
Target: 865
BUY
Karvy Stock Broking
15-Mar-18
Price @ Call: 786.62
Target: 830
HOLD
Motilal Oswal
7-Feb-18
Price @ Call: 801.65
Target: 940
BUY
LUPIN Share Price Target - Broker Reports - 2017
JM Financial
13-Nov-17
Price @ Call: 831.84
Target: 1140
BUY
Sharekhan
9-Nov-17
Price @ Call: 842.55
Target: 1050
HOLD
Motilal Oswal
8-Nov-17
Price @ Call: 860.5
Target: 1000
BUY
HDFC Securities
3-Nov-17
Price @ Call: 1053.63
Target: 1565
BUY
Motilal Oswal
31-Oct-17
Price @ Call: 1027.55
Target: 1215
BUY
ICICIdirect.com
31-Oct-17
Price @ Call: 1027.55
Target: 1105
HOLD
KRChoksey
31-Oct-17
Price @ Call: 1027.55
Target: 1187
BUY
Motilal Oswal
12-Oct-17
Price @ Call: 1045.5
Target: 1215
BUY
ICICIdirect.com
12-Oct-17
Price @ Call: 1045.5
Target: 1280
BUY
Motilal Oswal
21-Sep-17
Price @ Call: 1002.2
Target: 1125
BUY
Angel Broking
7-Aug-17
Price @ Call: 993
Target: 1467
BUY
HDFC Securities
4-Aug-17
Price @ Call: 993
Target: 1650
BUY
Motilal Oswal
4-Aug-17
Price @ Call: 995
Target: 1125
BUY
KRChoksey
3-Aug-17
Price @ Call: 995
Target: 1169
BUY
Edelweiss
3-Aug-17
Price @ Call: 993
Target: 1010
HOLD
Edelweiss
18-Jul-17
Price @ Call: 1156
Target: 1170
HOLD
Geojit Financial Services
10-Jul-17
Price @ Call: 1135
Target: 1650
BUY
HDFC Securities
25-May-17
Price @ Call: 1228
Target: 1800
BUY
ICICIdirect.com
25-May-17
Price @ Call: 1140
Target: 1335
BUY
Axis Direct
15-Feb-17
Price @ Call: 1435.31
Target: 1600
HOLD
Khambatta Securities
13-Feb-17
Price @ Call: 1490
Target: 1771
BUY
KRChoksey
10-Feb-17
Price @ Call: 1495
Target: 1730
BUY
ICICIdirect.com
10-Feb-17
Price @ Call: 1478
Target: 1760
BUY
Prabhudas Lilladher
10-Feb-17
Price @ Call: 1495
Target: 1730
ACCUMULATE
Religare
9-Feb-17
Price @ Call: 1491.35
Target: 1660
HOLD
Motilal Oswal
9-Feb-17
Price @ Call: 1490
Target: 1850
BUY
Centrum
9-Feb-17
Price @ Call: 1491
Target: 1880
BUY
LUPIN Share Price Target - Broker Reports - 2016
Geojit Financial Services
27-Dec-16
Price @ Call: 1405
Target: 1667
BUY
KRChoksey
10-Nov-16
Price @ Call: 1529
Target: 1769
BUY
ICICIdirect.com
10-Nov-16
Price @ Call: 1529
Target: 1890
BUY
Prabhudas Lilladher
7-Nov-16
Price @ Call: 1421
Target: 1650
ACCUMULATE
HDFC Securities
14-Oct-16
Price @ Call: 1465.75
Target: 2040
BUY
IIFL
25-Aug-16
Price @ Call: 1531.75
Target: 1650
ACCUMULATE
Karvy Stock Broking
11-Aug-16
Price @ Call: 1569.5
Target: 1831
BUY
Axis Direct
10-Aug-16
Price @ Call: 1608
Target: 1800
BUY
Khambatta Securities
10-Aug-16
Price @ Call: 1566.95
Target: 1804
BUY
Enochventures.com
12-Jul-16
Price @ Call: 1672.1
Target: 1900
HOLD
Dynamic Levels
29-Jun-16
Price @ Call: 1430
Target: 1693
BUY
Religare
20-May-16
Price @ Call: 1539.05
Target: 1660
HOLD
- keyboard_arrow_down
LUPIN Peer Stocks - Share Price Targets
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.